# US 2026/0092328 A1 · Microrna biomarkers for multi cancer early detection test (mced)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092328 A1
- Document ID: US20260092328A1
- Status: Published application
- Kind: A1
- Application number: 19/123,700
- Filed: 2023-10-24
- Published: 2026-04-02
- Earliest claimed: 2022-10-24
- Assignees: University of Southampton
- Applicants: University of Southampton
- Inventors: Andrew George SHAPANIS; Paul James Stuart SKIPP
- Web page: https://patentgrep.com/patent/US20260092328A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to a method of diagnosing a cancer in a subject, wherein the method comprises determining the expression level of a set of miRNAs in a sample obtained from the subject. The invention also relates to a method of identifying the site of localisation of a cancer in a subject. The invention also provides method of treating a subject with cancer.

## Claims

### Claim 1

A method of diagnosing a cancer in a subject, wherein the method comprises:
i. providing a biological sample obtained from the subject;
ii. determining the expression level of at least three miRNAs in the sample obtained from the subject;
iii. using the results from (ii) to determine if the subject has a cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the at least three miRNAs are selected from Table 1.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the at least three miRNAs comprise or consist of three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, 24 or more, 25 or more, 26 or more, 27 or more, 28 or more, 29 or more, 30 or more, 31 or more, 32 or more, 33 or more, 34 or more, 35 or more, 36 or more, 37 or more, 38 or more, 39 or more, 40 or more, 41 or more, 42 or more, 43 or more, 44 or more, 45 or more, 46 or more, 47 or more, 48 or more, 49 or more, or 50 of the miRNAs in Table 1.

### Claim 4 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein the at least three miRNAs may comprise or consist of miRNAs having the sequence of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3.

### Claim 5 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein the at least three miRNAs may comprise or consist of miRNAs having the sequences of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

### Claim 6 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein the at least three miRNAs may comprise or consist of miRNAs having the sequence of all of SEQ ID NOs: 1-50.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any of claims 1-6, wherein a machine learning model is used to determine if the subject has cancer from the expression levels of the at least three miRNAs.

### Claim 8 (depends on 7)

The method of claim 7, wherein the machine learning model comprises a support vector machine.

### Claim 9 (depends on 8)

The method of claim 8, wherein the vector machine employs a radial kernel.

### Claim 10 (depends on 7, 8, 9)

The method of any of claims 7-9, wherein the method comprises using a second machine learning model to identify what type of cancer is present in the event that the first machine learning model determines that the subject has cancer.

### Claim 11 (depends on 10)

The method of claim 10, wherein the second machine learning model comprises a feedforward artificial neural network.

### Claim 12 (depends on 11)

The method of claim 11, wherein the feedforward artificial neural network comprises a single hidden layer, and/or at least one hidden layer.

### Claim 13

A method of determining the localisation of a cancer in a subject, comprising:
i. providing a biological sample obtained from the subject;
ii. determining the expression level of a panel of miRNAs, the panel comprising miRNAs having the sequences of at least three of, up to all of, SEQ ID NOs 1-50, in the sample obtained from the subject; and
iii. using the results from (ii) to determine a location of the cancer, optionally wherein a second machine learning model is used to identify the location of the cancer in the event that the first machine learning model determines that the subject has cancer, optionally wherein the second machine learning model comprises a feedforward artificial neural network.

### Claim 14 (depends on 13)

The method of claim 13, wherein the at least three miRNAs comprise or consist of miRNAs having the sequence of all miRNAs of Table 2.

### Claim 15 (depends on 13)

The method of claim 13, wherein the three or more miRNAs comprise or consist of the 30 miRNAs of Table 2, the first 25 miRNAs of Table 2, the first 20 miRNAs of Table 2, the first 15 miRNAs of Table 2, or the first 10 miRNAs of Table 2.

### Claim 16

The method of any preceding claim, wherein the biological sample is a biological fluid, such as a blood, plasma, serum, urine or cerebrospinal fluid sample.

### Claim 17

The method of any preceding claim, wherein the cancer is a solid cancer, optionally wherein the solid cancer is selected from the group consisting of: bladder cancer, bone and soft tissue sarcoma, breast cancer, colorectal cancer, oesophageal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma (HCC), lung cancer, ovarian cancer, pancreatic cancer, or prostate cancer.

### Claim 18

The method of any preceding claim, wherein the cancer is stage 0 cancer, stage 1 cancer, stage 2 cancer, stage 3 cancer or stage 4 cancer

### Claim 19

A method of treating a subject with cancer, wherein the method comprises:
i. providing a biological sample obtained from the subject;
ii. determining the expression level of at least three miRNAs in the sample obtained from the subject;
iii. using the results from (ii) to determine if the subject has a cancer; and
iv. administering an anti-cancer therapeutic to the subject if the subject is determined to have cancer.

### Claim 20 (depends on 17)

The method of claim 17, wherein the at least three miRNAs may comprise or consist of miRNAs having the sequence of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3.

### Claim 21 (depends on 17)

The method of claim 17, wherein the at least three miRNAs may comprise or consist of miRNAs having the sequences of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

### Claim 22 (depends on 17)

The method of claim 17, wherein the at least three miRNAs may comprise or consist of miRNAs having the sequence of all of SEQ ID NOs: 1-50.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A kit for carrying out the method of any of claims 1-22, wherein the kit comprises one or more reagents for determining the expression level of the at least three miRNAs.

### Claim 24 (depends on 24)

The kit of claim 24, wherein the reagents are one or more oligonucleotide primers specific for each of the at least three miRNAs.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

the kit of claim 23 or claim 24, further comprising a set of instructions which set out to the reader the details and information required to perform the method of any of claims 1-23.
